NK-1 receptor antagonists (substance P blockers) represent a new pharmacological paradigm with applications in emesis (aprepitant approved), pain, depression, and inflammatory conditions — multi-indication potential.
Key findingNK-1 receptor antagonists (substance P blockers) represent a new pharmacological paradigm with applications in emesis (aprepitant approved), pain, dep
What the researchers found
NK-1 receptor antagonists (substance P blockers) represent a new pharmacological paradigm with applications in emesis (aprepitant approved), pain, depression, and inflammatory conditions — multi-indication potential.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
NK-1 receptor antagonists: a new paradigm in pharmacological therapy.
Current medicinal chemistry, 18(12), 1820-31
Citation
Muñoz, M; Coveñas, R. (2011). NK-1 receptor antagonists: a new paradigm in pharmacological therapy.. Current medicinal chemistry, 18(12), 1820-31.